GeneDx (WGS)

Search documents
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
ZACKS· 2025-07-28 14:31
Core Insights - GeneDx Holdings Corp. is set to report its second-quarter 2025 results on July 29, with strong expectations based on previous performance and estimates [1][10] Financial Performance - The company reported first-quarter adjusted earnings of 28 cents per share, exceeding the Zacks Consensus Estimate by 154.55%, marking a consistent trend of earnings beats over the past four quarters with an average surprise of 145.82% [1] - The Zacks Consensus Estimate for second-quarter revenues is $84.7 million, indicating a 20.1% increase from the previous year, while the EPS estimate is 10 cents, reflecting a significant year-over-year increase of 190.9% [2] Estimate Revisions - Earnings estimates have increased by 11.1% to 10 cents in the last 30 days, indicating positive sentiment ahead of the earnings announcement [3] Growth Drivers - Revenue growth is anticipated to be driven by Exome and genome tests, with a notable 24% year-over-year increase in test volume during the first quarter, contributing to a 62% revenue increase [4] - The acquisition of Fabric Genomics is expected to enhance GeneDx's capabilities in AI-powered genomic interpretation, facilitating a more comprehensive approach to genomic medicine [5] - The launch of ultraRapid Whole Genome Sequencing is projected to provide faster diagnoses for neonatal and pediatric patients, further contributing to revenue growth [7] Operational Efficiency - The company achieved a 56% growth in adjusted gross profit from continuing operations in the first quarter, leading to a 69% increase in gross margin, with expectations of continued operational efficiency in the second quarter [8] Market Position - GeneDx's strong performance in pediatric neurology and new testing indications is likely to drive outpatient volume growth, positioning the company favorably in the market [9]
ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS
GlobeNewswire News Room· 2025-07-26 17:00
Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased GeneDx securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A report by Grizzly Research accused GeneDx of committing widespread fraud, claiming that its growth is an illusion driven by fraudulent schemes [3] Group 2: Stock Performance - Following the allegations from Grizzly Research, GeneDx's stock price fell by $4.84, or 6.7%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]
GeneDx CFO Sells More Than Half of His Shares
The Motley Fool· 2025-07-25 18:40
Company Overview - GeneDx Holdings is a healthcare technology company that integrates AI and machine learning with clinical and genomic data, focusing on precision medicine and individualized patient care [7] - The company has a market capitalization of $2.29 billion and reported a revenue of $330 million with a net income of -$38.6 million for the trailing twelve months [6] Recent Financial Performance - GeneDx Holdings shares have appreciated by 141.5% over the past year as of July 11, 2025 [5] - The company reported a 42% year-over-year increase in revenue for the first quarter, driven by high volumes of exome and genome tests [9] - Revenue from exome and genome tests accounted for 82% of GeneDx's total Q1 revenue, with the net loss for the quarter shrinking to $6.5 million from $20 million in the prior-year period [10] Insider Activity - On July 11, 2025, Kevin Feeley, CFO of GeneDx Holdings, sold 5,278 shares, reducing his holdings to 3,392 shares, which represents approximately 0.01% of total shares outstanding [1][4] - This sale is consistent with Feeley's recent trading patterns, as it is near the median trade size for him over the last several quarters [3] Growth Catalysts - GeneDx has strong growth prospects, particularly following its acquisition of Fabric Genomics, which enhances its AI-driven test interpretations and expands its genomics testing portfolio [12] - The company is targeting a larger patient population by expanding testing to outpatient pediatrics, NICU patients, and newborns [11] - Management has raised its full-year revenue guidance to a range of $360 million to $375 million, up from the previous forecast of $350 million to $360 million [10]
GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ZACKS· 2025-07-22 15:07
GeneDx Holdings Corp. (WGS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Jul ...
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group
Prnewswire· 2025-07-22 09:28
Core Viewpoint - DJS Law Group is investigating GeneDx Holdings Corp. for potential violations of securities laws, focusing on allegations of fraudulent activities and misleading statements made by the company [1][2]. Group 1: Investigation Details - The investigation is centered on whether GeneDx made false or misleading statements or failed to disclose material information relevant to investors [2]. - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at manipulating Medicaid and Medicare programs to artificially inflate revenue [2]. - Allegations include that GeneDx inflated earnings through the unlawful practice of "code stacking," which allows billing for services that do not meet appropriate standards [2]. Group 2: Insider Trading Allegations - The report also alleges that CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting without participating in open market acquisitions, suggesting insider awareness of potential threats to the business [2]. Group 3: DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [2].
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?
ZACKS· 2025-07-17 14:56
GeneDx Holdings Corp. (WGS) closed the last trading session at $80.47, gaining 24.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $101.53 indicates a 26.2% upside potential.The average comprises eight short-term price targets ranging from a low of $78.00 to a high of $115.00, with a standard deviation of $14.73. While the lowest estimate indicates a decline of 3.1% from the curr ...
GeneDx: Strong Testing Volume And An Invaluable Genomic Database
Seeking Alpha· 2025-07-15 06:52
Core Insights - The article emphasizes a holistic investment approach in healthcare equities, integrating both top-down and bottom-up valuation techniques [1] - It highlights the importance of detailed company analysis, particularly focusing on capital structure and debt covenants, which significantly influence equity valuation [1] Summary by Categories Investment Approach - The investment strategy involves a comprehensive evaluation that combines macroeconomic factors with specific company metrics [1] Company Analysis - Detailed examination of companies is crucial, with particular attention to their capital structure and debt obligations, as these factors can greatly affect their market valuation [1]
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
MarketBeat· 2025-06-30 18:21
Core Insights - The biopharmaceutical industry is characterized by volatile stock movements, with companies often experiencing rapid rallies and sell-offs due to trial data and product developments [1][2] Company Summaries Nektar Therapeutics (NKTR) - Nektar Therapeutics has seen a significant increase in share price following successful Phase 2b trial results for its immunotherapy drug candidate, Rezpeg, which targets conditions like eczema affecting approximately 10 million patients in the U.S. [4][6] - The stock price surged over 300% within five trading days, reaching just under $30 per share, although it remains significantly lower than its all-time high of over $1,500 from early 2018 [5][6] - Analysts are optimistic, with six out of seven rating the stock as a Buy and a consensus price target of $84.17, indicating a potential upside of about 227% [6] Cidara Therapeutics (CDTX) - Cidara Therapeutics experienced a nearly 150% increase in share price following positive Phase 2b trial results for CD388, a non-vaccine treatment for seasonal influenza, which demonstrated a 76% protection rate for 24 weeks [8][9] - The stock reached its highest level since spring 2021, and analysts are bullish, with all nine ratings being Buy, although the company issued $250 million in new stock, which could dilute existing shares [10] GeneDx Holdings Corp. (WGS) - GeneDx has seen a recent stock surge of nearly 40% after announcing a partnership with Galatea Bio for genetic testing and updated guidance from the American Academy of Pediatrics recommending genomic sequencing for children with developmental delays [12][14] - Despite topping analyst predictions for first-quarter sales and raising revenue guidance for FY 2025, the stock had previously plummeted by almost 50% [12][13] - Six out of eight analysts rate WGS as a Buy, but concerns remain regarding its high valuation and competition in the genomic diagnostics space [15]
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
ZACKS· 2025-06-24 12:36
Core Viewpoint - GeneDx Holdings Corp. (WGS) shares experienced a significant increase of 19% in the last trading session, closing at $79.71, driven by strong trading volume and investor optimism regarding its strategic collaboration with Galatea Bio [1][2]. Company Performance - GeneDx is expected to report quarterly earnings of $0.09 per share, reflecting a year-over-year increase of 181.8%. Revenue projections stand at $84.7 million, which is a 20.1% increase compared to the same quarter last year [3]. - The consensus EPS estimate for GeneDx has remained unchanged over the past 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - GeneDx operates within the Zacks Medical Services industry, where another company, Progyny (PGNY), closed the last trading session down by 0.9% at $20.79, with a monthly return of 2.2% [4]. - Progyny's consensus EPS estimate for its upcoming report is $0.42, which represents a decrease of 2.3% from the previous year, and it also holds a Zacks Rank of 3 (Hold) [5].
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire News Room· 2025-06-19 19:43
Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - The investigation is prompted by a report from Grizzly Research, which claims that GeneDx is involved in widespread fraud, manipulating Medicaid and Medicare systems to inflate revenue [3]. - Following the allegations, GeneDx's stock experienced a decline of 6.7% on February 5, 2025 [3]. Group 2: Class Action Details - Shareholders who purchased GeneDx securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].